Who got it right? Stock Guru!
Renhuang Pharmaceuticals, Inc. , RHGP, is still on the charts … but barely. They are adding more room at the top!
Monday’s shares went up 0.5% to $2.01. 30,595 was the volume.
Who told you about RHGP and a little thing called Siberian Gensing?
Who told you straight?
Who sent you to Pub Med and gave you the inside track on the importance of this medicinal drug?
Stock Guru!
Who explained this down to earth, very sensible business plan? Renhuang Pharmaceuticals, Inc. (RHGP) believes a company should generate revenue to support its research and development! Their earnings support this philosophy.
Stock Guru!
Who told you the fiscal year-to-date results covering the nine months from October 1, 2006 to July 31, 2007, indicate net earnings of $8.46 million on solid sales of about $21 million, more than doubling the net earnings of $3.08 million for the Company’s operating subsidiary for the same period of the previous year.
Stock Guru!
Who told you RHGP controls an estimated 70% of China’s natural resources of Acanthopanax (also known as Siberian Ginseng), the Company possesses a unique competitive edge and occupies a dominant market position in Acanthopanax-based medicinal and nutraceutical products.
Stock Guru!
Pub Med the U.S. National Library of Medicine that includes over 17 million citations from MEDLINE and other life science journals for biomedical articles profiles Siberian Gensing. Link here to read what Pub Med has to say about Acanthopanax.
Stock Guru Gets It Right.
Source:
Pub Med and
Renhuang Pharmaceuticals, Inc.
No. 281, Taiping Road, Taiping District
Harbin, Heilongjiang Province, 150050
P. R. China
About Renhuang Pharmaceuticals, Inc.: Renhuang Pharmaceuticals, located in Harbin of Heilongjiang Province in Northeast China, is a leading integrated developer, manufacturer and distributor of a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products. The Company provides three major product lines including the Acanthopanax-based natural medicinal products, Shark Power Health Care series and Traditional Chinese Medicines. Renhuang’s key product line is Acanthopanax-based products, an effective natural medicine in treating depression and melancholy and offering various other health benefits. By controlling an estimated 70% of China’s natural resource of Acanthopanax (also known as Siberian Ginseng), the Company has a dominant market position in Acanthopanax-based natural medicines. The Company distributes its products through a multi-layer sales network of over 2000 sales agents. Its products are not only sold nationwide but also exported to Russia and Southeast Asia. Renhuang has established a multi-channel research and development infrastructure composed of in-house researchers, a post-doctoral working center, and collaboration with well known institutions and scientists. The Company has achieved a significant progress in research & development of standard extraction, separation of effective components, and medication with specificity. Several of these products have already been submitted for approval by the State Food and Drug Administration (”SFDA”). These products are expected to have a substantial upside growth potential due to their insufficient supply in China. In manufacturing, the Company strictly follows the international GMP certified quality standards and system by utilizing cutting-edge technologies, the state of the art equipment, and the proprietary innovative and award winning processes.
Safe Harbor Statement: This press release contains certain statements that may include ‘forward-looking statements’ as defined in the Securities Act of 1933, and the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein are ‘forward-looking statements.’ Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with and available from the Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Disclosure: Pentony Enterprises LLC has been compensated $12,300.00 for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com.
